Nuvectis Pharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Nuvectis Pharma Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- NVCT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001875558
Board of directors
-
James F. Oliviero III · DirectorSince 2023
-
Juan Sanchez · DirectorSince 2025
-
Kenneth Hoberman · DirectorSince 2023
-
Matthew L. Kaplan · DirectorSince 2023
-
Ron Bentsur · Director · Chairman & CEOSince 2023
Chief executives
Ron Bentsur
· Chairman & CEO
Dates unknown
Board connections
2 of this board's directors also sit on 2 other boards.
- via Ron Bentsur
- via Kenneth Hoberman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $2,291,193
- 8 purchases by 4 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 3, 2026 | Carson Michael J. Officer (Vice President, Finance) | Grant or award | +30,000 | — | — |
| Jun 30, 2026 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Open-market purchase | +12,500 | $20.00 | $250,000 |
| Jun 30, 2026 | Mosseri Marlio Charles 10% owner | Open-market purchase | +50,000 | $18.32 | $916,000 |
| Jun 11, 2026 | Kenneth Hoberman Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | James F. Oliviero III Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | Juan Sanchez Director | Grant or award | +35,000 | — | — |
| Jun 11, 2026 | Matthew L. Kaplan Director | Grant or award | +35,000 | — | — |
| Jan 6, 2026 | Shemesh Shay Officer (Chief Dev. & Ops. Officer) | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Poradosu Enrique Officer (Chief Science & Business Off) | Grant or award | +150,000 | — | — |
| Jan 6, 2026 | Carson Michael J. Officer (Vice President, Finance) | Grant or award | +61,200 | — | — |
| Nov 5, 2025 | Ron Bentsur Director, Officer (Chairman & CEO), 10% owner | Open-market purchase | +5,000 | $5.72 | $28,600 |
| Nov 5, 2025 | Juan Sanchez Director | Open-market purchase | +13,000 | $5.79 | $75,270 |
| Nov 5, 2025 | Matthew L. Kaplan Director | Open-market purchase | +11,000 | $5.84 | $64,240 |
| Oct 27, 2025 | Mosseri Marlio Charles 10% owner | Open-market purchase | +72,836 | $6.28 | $457,410 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.